Literature DB >> 15219790

From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells.

Sam C Brooks1, Debra F Skafar.   

Abstract

A variety of compounds, including the selective estrogen receptor (ER) modulators tamoxifen and raloxifene, phytoestrogens such as genistein, and xenoestrogens such as bisphenol, bind to the estrogen receptor and elicit biological responses. Structural studies have linked the altered activity of compounds such as 4-hydroxytamoxifen, raloxifene, genistein, and tetrahydrochrysene, which have substantially different structures from estradiol (E2), to differences in the positioning of the critical "helix 12" within the ligand-binding domain (LBD) of the ER-ligand complex. However, subtle permutations of the E2 molecule would also be expected to modulate the pattern of responses within a cell. Forty-two ligands were constructed by the addition or relocation of double bonds, hydroxyl, keto, amino, and nitro substituents throughout the estra-l,3,5(10)-triene (estratriene) ring system. In this review, we summarize the effects of subtle changes in the estratriene molecule on the ability of the receptor complex to stimulate the growth of MCF-7 cells, or affect the expression of four estrogen-regulated genes (progesterone receptor, pS2 protein, cathepsin D, and tissue plasminogen activator), as well as undergo nuclear processing and downregulate ERalpha mRNA. The affinity of these ligands for, and mechanism of their binding with, the ERalpha have been measured, along with their effect on the conformation of the ER-ERE complex. In particular, two A-ring isomers of E2, 2- and 4-hydroxyestratriene-17beta-ol, display gene selective activity within MCF-7 cells which is dependent on complex endogenous promoters, an intact AF-2 and is sensitive to the level of SRC-1. Both of these A-ring isomers function as antiestrogens. Molecular modeling of these two A-ring isomers complexed with the ER ligand-binding domain supports the idea that the conformation of the LBD is affected by subtle changes in the estratriene structure. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219790     DOI: 10.1016/j.steroids.2004.03.014

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  6 in total

1.  Effects of the protein tyrosine kinase inhibitor genistein and taurine on retinal function in isolated superfused retina.

Authors:  Matthias Lüke; Ralf Krott; Max Warga; Peter Szurman; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Toni Schneider; Christoph Lüke
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

2.  The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors.

Authors:  J W Roy; E A Cowley; J Blay; P Linsdell
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

3.  Pituitary tumor transforming gene binding factor: a new gene in breast cancer.

Authors:  Rachel J Watkins; Martin L Read; Vicki E Smith; Neil Sharma; Gary M Reynolds; Laura Buckley; Craig Doig; Moray J Campbell; Greg Lewy; Margaret C Eggo; Laurence S Loubiere; Jayne A Franklyn; Kristien Boelaert; Christopher J McCabe
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

4.  Apigenin suppresses cancer cell growth through ERbeta.

Authors:  Paul Mak; Yuet-Kin Leung; Wan-Yee Tang; Charlotte Harwood; Shuk-Mei Ho
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

5.  Microarray analysis on gene regulation by estrogen, progesterone and tamoxifen in human endometrial stromal cells.

Authors:  Chun-E Ren; Xueqiong Zhu; Jinping Li; Christian Lyle; Sean Dowdy; Karl C Podratz; David Byck; Hai-Bin Chen; Shi-Wen Jiang
Journal:  Int J Mol Sci       Date:  2015-03-13       Impact factor: 5.923

6.  Toxicological testing of syringaresinol and enterolignans.

Authors:  Verena Kirsch; Tamara Bakuradze; Elke Richling
Journal:  Curr Res Toxicol       Date:  2020-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.